TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04305860

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Modified starch without flavoring
Description: Each patient of this group receives the thickener during three days of hospitalization

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mofidied starch with Bi1 aromas
Description: Each patient of this group receives the thickener and 5 flavorings during three days of hospitalization

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xanthan gum without flavoring
Description: Each patient of this group receives the thickener during three days of hospitalization

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xanthan gum with Bi1 aromas
Description: Each patient of this group receives the thickener and 5 flavorings during three days of hospitalization
Study: NCT02469233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Intervention for Sleep and Circadian Dysfunction
Description: The intervention is a modular treatment composed of core modules that are given to all participants and modules that are delivered based on the need/s of the participants. The interventions are all cognitive behavioral.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transdiagnostic Intervention for Sleep and Circadian Dysfunction
Description: The intervention is a modular treatment composed of core modules that are given to all participants and modules that are delivered based on the need/s of the participants. The interventions are all cognitive behavioral.
Study: NCT03184571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemcentinib; pembrolizumab
Description: Bemcentinib is a selective Axl kinase inhibitor; pembrolizumab is a PD-1 inhibitor
Study: NCT00645671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Loteprednol Etabonate Ophthalmic Ointment
Description: 1/2 inch ribbon four times a day for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of Loteprednol Etabonate Ophthalmic Ointment
Description: 1/2 inch ribbon four times a day for 14 days
Study: NCT02693717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV
Study: NCT03675529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training bout
Description: Patients randomized to the HIIT bout will perform one single supervised High Intensity Interval Training bout consisting firstly of a wattmax test on a stationary bike, in order to set the training intensity. This is followed by 10 minutes at low intensity at approximately 30% of wattmax. Subsequently patients will perform 16 min with 4 cycles with High and Low intensity. HI intervals consisting of 1 min with 100% of wattmax followed by 3 min recovery with the intensity load of 30% of wattmax.
Study: NCT03117361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plitidepsin
Description: Patients received plitidepsin as a 3-hour i.v. infusion at a dose of 5 mg/m2 on Days 1 and 15 every Four Weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: BTZ as a 3-5 second bolus s.c. injection at a dose of 1.3 mg/m2 on Days 1, 4, 8 and 11 every four weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: DXM orally at a dose of 40 mg/day on Days 1, 8, 15 and 22 every four weeks
Study: NCT03639129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced mammography
Description: Contrast-enhanced mammography was FDA approved in 2012 and is currently being used in both clinical and research settings at breast imaging centers throughout the world

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Standard of care
Study: NCT02359279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sodium iodide
Description: Comparison of control radiographs made before application of sodium iodide and test radiograph after application.
Study: NCT04017871

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MRI
Description: MRI at baseline and J90

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI at baseline and J90

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electro-Encephalography-High Density (children with unilateral PC only)
Description: Electro-Encephalography-High Density (children with unilateral PC only) at baseline and J90

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electro-Encephalography-High Density (children with unilateral PC only)
Description: Electro-Encephalography-High Density (children with unilateral PC only) at baseline and J90

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 3D and EMG analysis
Description: 3D and EMG analysis at baseline and J90

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D and EMG analysis
Description: 3D and EMG analysis at baseline and J90

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: care and classic activities
Description: physiotherapy and psychomotility. As needed weekly sessions of speech therapist or orthoptist and daily activities of the child.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: care and classic activities
Description: physiotherapy and psychomotility. As needed weekly sessions of speech therapist or orthoptist and daily activities of the child.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Accelerometers
Description: During 5 days a sensor at each wrist to quantify their movement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerometers
Description: During 5 days a sensor at each wrist to quantify their movement.
Study: NCT02296762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Sirolimus tablets 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus tablets 2 mg
Study: NCT04412798

Intervention type: OTHER
Group type: OTHER
Intervention: orange juice concentrate
Description: 250mL of 100% orange juice made from concentrate

Intervention type: OTHER
Group type: OTHER
Intervention: Sugar-sweetened orange-flavoured beverage
Description: Sugar-sweetened orange-flavoured beverage, energy-matched to the orange juice condition

Intervention type: OTHER
Group type: OTHER
Intervention: Whole orange juice with skin removed
Description: Whole orange pieces with skin removed, energy-matched to the orange juice condition
Study: NCT00680615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored, enhanced condition
Description: Intervention will provide a personalized, interactive tobacco cessation Web application, based on existing empirically validated smokeless tobacco cessation programs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: The Usual Care condition will provide access to typical smokeless tobacco cessation information and links to commonly available Web-based smokeless tobacco cessation resources.
Study: NCT03758235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 100 UNT Injection [Xeomin]
Description: Incobot/A intradetrusor injections under cystscopic guidance, with local anaethesia in an outpatient basis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 100 UNT Injection [Xeomin]
Description: Incobot/A intradetrusor injections under cystscopic guidance, with local anaethesia in an outpatient basis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA 100 UNT [Botox]
Description: Onabot/A intradetrusor injections under cystscopic guidance, with local anaethesia in an outpatient basis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA 100 UNT [Botox]
Description: Onabot/A intradetrusor injections under cystscopic guidance, with local anaethesia in an outpatient basis
Study: NCT02479113

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: At 12 - 32 weeks: All patients need blood sampling for OGTT + insulin + C-peptide + fasting triglyceride + NEFA At 36 weeks/ delivery: All patients need blood sampling for fasting glucose + insulin + C-peptide + fasting triglyceride + NEFA At 36 weeks/ delivery: only GDM patients need blood sampling for HbA1c + fructosamine

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: At 12 - 32 weeks: All patients need blood sampling for OGTT + insulin + C-peptide + fasting triglyceride + NEFA At 36 weeks/ delivery: All patients need blood sampling for fasting glucose + insulin + C-peptide + fasting triglyceride + NEFA At 36 weeks/ delivery: only GDM patients need blood sampling for HbA1c + fructosamine

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: At 12 - 32 weeks: All patients need blood sampling for OGTT + insulin + C-peptide + fasting triglyceride + NEFA At 36 weeks/ delivery: All patients need blood sampling for fasting glucose + insulin + C-peptide + fasting triglyceride + NEFA At 36 weeks/ delivery: only GDM patients need blood sampling for HbA1c + fructosamine
Study: NCT00836446

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical activity
Description: physical activity routines 5 times a weeks for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity
Description: physical activity routines 5 times a weeks for 12 weeks.
Study: NCT01745614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg tablets
Description: Reference product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg tablets
Description: Reference product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg tablets
Description: Test product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg tablets
Description: Test product
Study: NCT03653312

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NMES
Description: Neuromuscular electrical stimulation of the paretic lower limb during exercise
Study: NCT00809094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine (NAC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01017081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy: three times per day, for 10 to 12 minutes, during hospital admission

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positioning and cough
Description: Non-mandatory request to maintain lateral positioning to improve air exchange and cough
Study: NCT03181685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone 25 MG subcutaneous
Description: A single subcutaneous administration per day from the day of oocyte retrieval

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micronized progesterone 200 MG
Description: 3 vaginal administrations per day from the day of oocyte retrieval

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant FSH
Description: Controlled ovarian stimulation (COS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant FSH
Description: Controlled ovarian stimulation (COS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix Acetate
Description: Inhibition of Luteinizing Hormone (LH) premature surge during COS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix Acetate
Description: Inhibition of Luteinizing Hormone (LH) premature surge during COS
Study: NCT01427270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone/Naloxone controlled-release
Description: Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone HCl controlled-release
Description: Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets to match OXN or OXY taken orally every 12 hours
Study: NCT03591224

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacogenomic Testing
Description: pharmacogenomic drug response test provides personalized insights on a patient's predicted response to medications based on metabolism

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacist Standard of Care
Description: Pharmacist providing standard of care as per usual practice
Study: NCT04202965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTG-300
Description: Active treatment with PTG-300 injected subcutaneously.
Study: NCT00272844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crystalline cholesterol oil-based suspension
Description: 200 mg/mL suspension of crystalline cholesterol in oil. Dosage (generally 75-300 mg/kg/day in divided doses) is based on initial cholesterol levels and regulated to increase, yet maintain, cholesterol levels no higher than normal ranges.
Study: NCT03326115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Visitation Program
Description: The Amputee Coalition's Peer Visitation Program (PVP) trains amputee peer supporters to properly navigate a new or less-experienced amputee through the process of rehabilitation. Peer support plays an important role, following the amputation of a limb, by allowing patients to meet other amputees and discuss lifestyle changes post-amputation. Subjects randomized to the PVP group will receive the intervention (visitation by a Certified Peer Visitor) immediately at amputation. Subjects randomized to the non-PVP group will not receive CPV visits immediately at amputation. Rather, they will receive delayed PVP intervention beginning 60 days after amputation and lasting a total of 60 days (or at 120 days post-amputation).
Study: NCT00933985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obatoclax mesylate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal vincristine sulfate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00502099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alpha 2a
Description: Injections: 180 ug once per week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Tablets, 1000-1200 daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alpha 2 b plus ribavirin
Description: Pegylated interferon alpha 2 b injections
Study: NCT04470479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine Hydrochloride
Description: Oral pilocarpine hydrochloride 5mg tablets were administered four times a day for 10 weeks to half the group of selected patients. The other half ingested placebo in the same way. At the end of this period and after two weeks of washing out the medications, the patients had to invert the treatments.
Study: NCT02472340

Intervention type: PROCEDURE
Intervention: Muscle Biopsy
Description: Muscle Biopsy

Intervention type: PROCEDURE
Intervention: Muscle Biopsy
Description: Muscle Biopsy
Study: NCT03471858

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical balloon
Description: To assess if a cervical balloon catheter (foleys catheter) for mechanical induction of labour is comparable to prostaglandin usage for induction of labour in women who have had a previous caesarean section.
Study: NCT04470479

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03058471

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: methotrexate arm will be given methotrexate starting at 10 mg weekly to be increased to 25 mg maximum in subsequent visits gradually
Study: NCT03471858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostaglandins
Description: Prostin will be used in the control arm.
Study: NCT03058471

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: this arm will be given NSAID to the tolerable full dose with pantoprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Description: inj. depot methyl prednisolone 80 mg ,2 doses deep intramuscularly given one week apart to all patients who have 5 or more swollen or tender joints
Study: NCT02694367

Intervention type: OTHER
Intervention: Investigate the MAP kinase signaling pathways through ERK and p-ERK proteins
Study: NCT03058471

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Description: inj. depot methyl prednisolone 80 mg ,2 doses deep intramuscularly given one week apart to all patients who have 5 or more swollen or tender joints
Study: NCT02885584

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency percussive ventilation
Study: NCT00822770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Phase I: Starting dose of 0 (escalating doses 80, 160, 240 mcg/kg) given daily subcutaneously in abdomen for 4 doses.~Phase II: Maximum Tolerated Dose (MTD) as determined in Phase I

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Phase I: Starting dose of 0 (escalating doses 80, 160, 240 mcg/kg) given daily subcutaneously in abdomen for 4 doses.~Phase II: Maximum Tolerated Dose (MTD) as determined in Phase I
Study: NCT01651754

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Seasonal influenza vaccination
Description: single dose of influenza vaccination
Study: NCT02237989

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: 1500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol+native collagen type 2
Description: paracetamol (1500 mg) + native collagen type 2 (10mg)
Study: NCT04040647

Intervention type: BEHAVIORAL
Intervention: mobilization and ambulation
Description: 6-min walk test (6-MWT)

Intervention type: BEHAVIORAL
Intervention: mobilization and ambulation
Description: 6-min walk test (6-MWT)
Study: NCT03900572

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV Vaccine
Description: Intramuscular injection, 3 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection, 3 doses
Study: NCT03665077

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Initial blood draw
Description: At baseline, patients will undergo a blood draw.
Study: NCT03821220

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized physical activity prescription
Description: Each patient will receive a personalized prescription of recommended physical activity including type of activity, duration and frequency.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized physical activity prescription
Description: Each patient will receive a personalized prescription of recommended physical activity including type of activity, duration and frequency.
Study: NCT03665077

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Initial SWE ultrasound
Description: At baseline, patients will undergo a sheer wave elastrography (SWE) ultrasound of their hands including wrists.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood draw at three months
Description: Blood drawn at three months to evaluate oxylipins.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood draw at six months
Description: Blood drawn at six months to evaluate oxylipins.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SWE ultrasound at six months
Description: SWE ultrasound at six months to evaluate tendon stiffness.
Study: NCT01826097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: La-Z-Boy Massage Chair Vibration Effect on Bladder Cancer Cell Concentration
Study: NCT02649517

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endomyocardial biopsy
Description: Endomyocardial biopsy will be performed through a puncture in the femoral vein. 3-6 samples taken under the control of myocardial echocardiography or flyuroskopii. Samples of biopsy material then transmitted Pathomorphology for immunohistochemistry, light microscope.
Study: NCT00822770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Dose of 10 mcg/kg subcutaneous injection beginning on day -9 daily for 6 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Dose of 10 mcg/kg subcutaneous injection beginning on day -9 daily for 6 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Dose of 40 mg/m\^2 beginning on Day -6 for four consecutive days.
Study: NCT03961516

Intervention type: DEVICE
Intervention: Frequently Sampled Oral Glucose Tolerance Test and CGM
Description: Patients will undergo a 2 hour frequently sampled oral glucose tolerance test while wearing an active FreeStyle Libre Pro sensor. Using as a tool to collect data.

Intervention type: DEVICE
Intervention: Frequently Sampled Oral Glucose Tolerance Test and CGM
Description: Patients will undergo a 2 hour frequently sampled oral glucose tolerance test while wearing an active FreeStyle Libre Pro sensor. Using as a tool to collect data.

Intervention type: DEVICE
Intervention: Frequently Sampled Oral Glucose Tolerance Test and CGM
Description: Patients will undergo a 2 hour frequently sampled oral glucose tolerance test while wearing an active FreeStyle Libre Pro sensor. Using as a tool to collect data.

Intervention type: RADIATION
Intervention: MRI Pancreas and Liver
Description: Patients will undergo an MRI of the pancreas and liver

Intervention type: RADIATION
Intervention: MRI Pancreas and Liver
Description: Patients will undergo an MRI of the pancreas and liver

Intervention type: RADIATION
Intervention: MRI Pancreas and Liver
Description: Patients will undergo an MRI of the pancreas and liver
Study: NCT04462822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent
Description: 2 inhalations of Test and Reference product in each study period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADVAIR DISKUS® 250/50
Description: 2 inhalations of Test and Reference product in each study period
Study: NCT02226263

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics Lactobacillus acidophilus boucardii
Description: Using sterile technique, the probiotic with 1x109 \[CFU\] Lactobacillus acidophilus boucardii strain was added at a dose of 125 mg/ kg/dose twice daily for 4 weeks to fresh supplement breast milk or formula for preterm infants.